Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sotalol vs Sotalex in Healthy Volunteers
NCT03799536Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotalol in cardiac arrhythmia (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve from time 0 to last measurable concentration at 72 hours. Started Jan 2019; status: completed.
02
Drugs
sotalol
03
Conditions
cardiac arrhythmia
Beyond the preview
Go deeper on NCT03799536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799536.